Document Detail


Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.
MedLine Citation:
PMID:  19301939     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUNDS AND METHODS: A higher degree of clinical efficacy with olmesartan compared with other angiotensin receptor blockers, has been reported by several sources. In this study of 31 examples of cases of essential hypertension, Holter electrocardiogram, ambulatory blood pressure monitoring and pulse wave velocity (PWV) measurements were performed before and after substituting olmesartan 20 mg for candesartan 8 mg antihypertensive drug therapy. RESULTS: Following the therapeutic change, daily average systolic and diastolic blood pressures were decreased by 6.7 +/- 9.3 mmHg and 3.6 +/- 8.3 mmHg, respectively, with olmesartan 20 mg; PWV was also significantly decreased. Holter electrocardiogram heart rate variability spectral analysis demonstrated that none of the very low frequency (VLF), high frequency (HF) and low frequency (LF)/HF components were significantly altered. However, a significant correlation was observed between the LF/HF component and blood pressure difference, when blood pressure and heart rate variability components in each individual case were studied. CONCLUSION: This study shows that olmesartan has a stronger antihypertensive effect in comparison to candesartan, and does not generate reflex sympathoexcitatory activity.
Authors:
Taiji Furukawa; Taketo Hatsuno; Yasunari Ueno; Kensuke Nagaoka; Yuji Watari; Takeshi Yamakawa; Toshio Sagawa; Takaaki Isshiki
Related Documents :
7073519 - Hemodynamic effects of hemodialysis and hemofiltration.
21069379 - Hyperoxia-induced alterations in cardiovascular function and autonomic control during r...
10550419 - Baroreflex sensitivity is depressed in microalbuminuric type i diabetic patients at res...
3379249 - Effect of changes in cardiac autonomic balance on blood pressure regulation in man.
1753239 - Sympathetic vascular function in patients with central dysautonomia.
9262349 - Promethazine affects autonomic cardiovascular mechanisms minimally.
17082719 - High pulse pressure and low mean arterial pressure: two predictors of death after a myo...
6469779 - Diaphragmatic fatigue in unanesthetized adult sheep.
15893709 - Closed-loop analysis of cardiovascular variability in rats under restraint stress.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Clinical drug investigation     Volume:  29     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2009  
Date Detail:
Created Date:  2009-03-23     Completed Date:  2009-05-14     Revised Date:  2011-01-11    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  257-64     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, School of Medicine, Teikyo University, Teikyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Benzimidazoles / therapeutic use*
Biphenyl Compounds / therapeutic use*
Blood Pressure / drug effects*,  physiology
Blood Pressure Monitoring, Ambulatory
Dose-Response Relationship, Drug
Drug Administration Schedule
Electrocardiography
Female
Heart Rate / drug effects*,  physiology
Humans
Hypertension / drug therapy*,  physiopathology
Imidazoles / therapeutic use*
Japan
Male
Tetrazoles / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Imidazoles; 0/Tetrazoles; 144689-24-7/olmesartan medoxomil; 145040-37-5/candesartan cilexetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidec...
Next Document:  Generic versus non-generic formulation of extended-release clarithromycin in patients with community...